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by separating abdominal at-risk organs from the target during irradiation, we created a percutaneous
paravertebral approach of high-dose-rate brachytherapy with hyaluronate gel injection (HGI). We
report a case treated with this technique.
METHODS AND MATERIALS: We encountered a patient with symptomatic regrowth of para-
aortic lymph node metastasis from prostatic cancer. He had previously received 58.4 Gy of radio-
therapy to the same region 12 months prior. Brachytherapy needles and a HGI needle were
deployed via the paravertebral approach under local anesthesia at our outpatient clinic.
RESULTS: A single dose of 22.5 Gy (equivalent to 60.94 Gy in 2 Gy per fraction schedule calcu-
lated at a/b5 10) was delivered to the target, with preservation of the surrounding small intestine
byHGIwithD2cc (minimumdose to themost irradiated volume of 2 mL) of 5.05 Gy. Therapeutic ratio
was 3.64 times higher for this brachytherapy plan compared with an intensity-modulated radiation
therapy plan. At followup at 1 year after brachytherapy, the symptoms had disappeared, tumor size
had reduced with no fluorodeoxyglucose accumulation, and prostate-specific antigen level had
decreased.
CONCLUSION: We consider that high-dose-rate brachytherapy with the HGI procedure offers
effective treatment even in this type of reirradiation situation.  2013 American Brachytherapy
Society. Published by Elsevier Inc. All rights reserved.Keywords: Reirradiation; Paraaortic lymph node; High-dose-rate brachytherapy; Hyaluronate; Risk organ; Prostate cancer;BowelIntroduction
Reirradiation is an effective treatment option in many
clinical situations. It is reported to have similar effectiveness
for local tumor control and pain reduction compared with
the initial irradiation (1e3), but it has also been associated
with significant incidence of late toxicity attributable tot 2011; received in revised form 24 November 2011;
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.1016/j.brachy.2011.12.004accumulated dose in at-risk organs, such as the small intes-
tine (3, 4). New technologies, such as intensity-modulated
radiation therapy and intensity-guided radiation therapy
(IMRT-IGRT) that facilitate accurate and selective dose
delivery still have limitations when the target is closely sur-
rounded by risk organs. In this context, we propose a liquid
spacing technique using hyaluronate gel injection (HGI)
with high-dose-rate brachytherapy (HDRBT) (5e10).
We encountered a patient with recurrent paraaortic lymph
nodemetastasis (PALNM) from prostate cancer that relapsed
12 months after radiotherapy of 58.4 Gy. We created both
IMRT-IGRT and HDRBT-HGI plans and compared the
therapeutic ratio of target dose and at-risk organs between
the two plans. The patient was treated and followed up for
more than 1 year; followup is ongoing. We discuss thehed by Elsevier Inc. All rights reserved.
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situation.Patient
We encountered a 72-year-old patient with relapsed
PALNM after initial radiotherapy (Fig. 1) complaining of
stiffness in the left leg. Three years before admitting to our
clinic, he visited a vicinity clinic with urinary difficulty
lasting for a few weeks. He was diagnosed with prostate
cancer (T3N1M1; Gleason score, 5þ 4; serum prostate-
specific antigen [PSA] level, 20.3 ng/mL); MRI revealed
seminal vesicle invasion and metastatic left iliac and para-
aortic nodal swelling. Hormonal therapy with 100 mg of
chlormadinone acetate (progesterone analog) daily was
immediately started and continued at the same dosage. Lutei-
nizing hormone-releasing hormone therapy caused allergic
responses and was not used. After 1 year, the patient noticed
macroscopic hematuria. His PSA level had reelevated
(4.8 ng/mL), and X-ray CTexamination revealed an increase
in the prostatic tumor size. The patient underwent initial
radiotherapy by external beam: a total of 70.4 Gy in
1.8e2.0 Gy fractions for the prostate and seminal vesicles
and a total of 58.4 Gy for the metastatic left iliac node and
paraaortic lymph nodes. These totals were a summation of
a wide-field treatment of 50.4 Gy in 1.8 Gy fractions
covering thewhole pelvis and paraaortic area and boost treat-
ments (Fig. 1b). One year later, his PSA level had reelevated
(1.13 ng/mL), and recurrent PALNM of 9.75 mL in volume
was detected. The patient was referred to our clinic for
reirradiation and chose to undergo IMRT-IGRT but changed
his mind before treatment and requested brachytherapy
instead.Fig. 1. Course of (a) serum prostate-specific antigen (PSA) level and (b) previo
node area and a narrow field (arrowheads) for selective boost treatment are show
metastasis.Before processing each treatment, informed consent was
obtained from the patient. Treatments were performed with
standard institutional approval.
IMRT planning
Using thin slice X-ray CT images (LightSpeed 16; GE
Healthcare, Buckinghamshire, UK) and Brainscan (version
5.2; Brainlab AG, Feldkirchen, Germany), an IMRT plan
was created to deliver 60 Gy in 3 Gy per fraction for 4
weeks. The spinal cord and kidneys were the critical organs
previously involved in the 50.4-Gy field.Brachytherapy preparation and planning
Preparation of hyaluronate gel
Forty milliliters of 0.16% sodium hyaluronate was
prepared with saline in advance, using a commercially avail-
able high-molecular hyaluronate (3.4 million daltons of
median molecular weight, 2.2 million of viscosity molecular
size; Suvenyl; Chugai/Roche, Tokyo, Japan). This hyaluro-
nate is a native-type bioproduct. Contrast medium (2 mL of
iopamiron 300 mg I/mL; Bayer Healthcare, Leverkusen,
Germany) was added to the gel.
Premedication
Treatment was performed at the outpatient clinic under
awake sedation with 25 mg of hydroxyzine pamoate and
5 mg of intravenous diazepam. The patient was able to report
his sensations during the procedure. Electrocardiogram,
arterial pressure of oxygen, respiration, and blood pressure
were monitored.us irradiation fields: a wider field (arrows) for pelvis and paraaortic lymph
n. EBRT5 external beam radiotherapy; PALNM5 paraaortic lymph node
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A 21-gauge steepled needle with side holes (improved
shape for straight-line insertion) was used for minimally
invasive gel injection. Microselectron system applicator nee-
dles (1.1 mm in external diameter and 20 cm in length) were
inserted to the target under X-ray CT guidance (10). The
CT-guided HGI procedure took approximately 30 min. The
space created by the gel injection was observed as an area
of contrast enhancement around the target (Fig. 2). Injection
of the gel created a spacer approximately 10-mm thick.
Fine-pitch (2 or 3 mm) X-ray CT images were then
acquired and transferred to the treatment planning computer.
A CT-based three-dimensional treatment plan was created
using a graphic optimization tool (PLATO version 14;
Nucletron, Veenendaal, The Netherlands) (Figs. 3 and 4).Doseevolume histogram analysis
In the brachytherapy plan, 22.5 Gy was prescribed to
100% of the target volume, and D2cc (minimum dose to
the most irradiated volume of 2 mL) of the small intestine
was 5.05 Gy (Fig. 5a). In the IMRT plan, 60 Gy in 3 Gy
per fraction was prescribed to the target, and D2cc to the
small intestine was 38 Gy in 1.8 Gy per fraction (Fig. 5b).
The equivalent dose for a 2 Gy fraction schedule was calcu-
lated using the linearequadratic (LQ) model, at a/b5 2
(GyELQ2,a/b52) for the small intestine and a/b5 10
(GyELQ2,a/b510) for the target. D2cc was 8.87 GyELQ2,a/b52
in the brachytherapy plan and 34.5 GyELQ2,a/b52 in the
IMRT plan (Fig. 5c). D1cc was 12 GyELQ2,a/b52 in the
brachytherapy plan and 38.9 GyELQ2,a/b52 in the IMRT
plan. Therapeutic of 100% planning target volume dose/
D2cc to the small intestine was 60.94 GyELQ2,a/b510/
8.87 GyELQ2,a/b525 6.87 for brachytherapy and 65
GyELQ2,a/b510/34.5 GyELQ2,a/b525 1.88 for IMRT, yield-
ing an enhancement factor of 3.64.Fig. 2. (a) X-ray CT image at the time of paraaortic node relapse (arrow). (b) O
after reirradiation shows no accumulation in the shrunken tumor (arrow). ImageIrradiation
After transporting the planning data to an iodine-192
remote afterloader system (Microselectron HDR Ir-192;
Nucletron, Veenendaal, The Netherlands), irradiation was
started. The irradiation took approximately 10 min.After irradiation and followup
The needles were removed after irradiation was complete,
and the patient was discharged after 2 h under observation.
There were no procedure-related complications. The patient
is regularly followed up at our affiliated clinics.Outcome
One week after the treatment, he reported disappearance
of the leg stiffness. No complications were found in follow-
up over 12 months after reirradiation.
Followup positron emission tomography-CT and MRI
studies taken 7months after the brachytherapy showed nega-
tive fluorodeoxyglucose accumulation and reduction of the
tumor size to 1 cm (Fig. 2b). The serum PSA level of carbo-
hydrate antigen 19-9 showed a remarkable decrease to
0.5 ng/mL at 10 months after reirradiation. At the present
13 months after reirradiation, there are no signs or symptoms
of abdominal complications and no evidence of recurrence at
the site of reirradiation.Discussion
Reirradiation of PALNM
Relapse of previously irradiated paraaortic lymph nodes
surrounded by small intestine is not a rare clinical situation,
but reirradiation in this situation is strictly limited becauseverlaid fluorodeoxyglucose-positron emission tomography image 9 months
s show the maximal cut surface of the tumor.
Fig. 3. Paravertebral approach: (a) X-ray CT image, (b) radiograph, (c) and photograph during the procedure showing the inserted brachytherapy applicator
needles (white arrowheads), needle for gel injection retention of contrast-enhanced hyaluronate gel (long white arrows), and the small intestines and
duodenums (short gray arrows).
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case, HGI-HDRBT provided a superior therapeutic ratio
compared with IG-IMRT and enabled curative dose treat-
ment with prominent therapeutic enhancement.
Intestinal tolerance
To date, no definitive consensus or guidelines exist
regarding the tolerance level of the small intestines both in
reirradiation and brachytherapy. In external beam reirradia-
tion, a cumulative bowel dose of 90 Gy was proposed as
a tolerance level (11). The small intestines are generally
thought to be more sensitive than the large bowel and which
tolerance level may be rather close to that of stomach. In bra-
chytherapy, Streitparth et al. (12) proposed D1cc thresholds
of 11 Gy for general gastric toxicity and 15 Gy for ulcera-
tion, which were equivalent to 35.75 and 63.75 Gy in 2 Gy
fraction schedule, respectively. We could choose a saferFig. 4. Dose distribution in reirradiation plans. Dose distribution in the (a) boption by comparing the doseevolume histogram, as in
Fig. 5c.
Procedural safety
The present technique of paravertebral insertion of appli-
cator needles and HGI to the subperitoneal space enabled
HDRBT to be achieved safely without significant radiation
to the small intestine. The paravertebral access route is
a safe percutaneous interventional maneuver that is also
used in retroperitoneal biopsies (13) and neurolysis.
Hyaluronate
Hyaluronate is a biosafe substance that is naturally present
in the extracellular space of human and animal tissues and is
degraded by our innate hyaluronidase. High-molecular-
weight native-type hyaluronate has been previously usedrachytherapy plan and (b) intensity-modulated radiation therapy plan.
Fig. 5. DVH analysis. DVH of the (a) brachytherapy and (b) IMRT plans and comparative DVH analysis of both plans using equivalent dose calculated by
the LQ model at a/b5 2 (c). GTV5 gross tumor volume; DVH5 doseevolume histogram; PTV5 planning target volume; IMRT5 intensity-modulated
radiation therapy; LQ model5 linearequadratic model.
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the spacing effect generally lasted for a few to several hours
depending on its concentration and anatomic factors of the
injected site. The radioprotective and anti-inflammatory
effects of hyaluronate are described previously (14e16).
Artificially cross-linked hyaluronate is a biodegradation-
resistant time-proof variant (Restylane SubQ; Q-Med,
Uppsala, Sweden) (17) that is used as a filler in cosmetic
augmentation. Prada et al. (18, 19) reported using this type
of hyaluronate for creating and maintaining space during
IMRT, HDRBT, and low-dose-rate brachytherapy for pros-
tate cancer. In addition, Vordermark et al. (20) commented
that a material with faster resolution would be suitable for
application to high-dose-rate intraluminal brachytherapy.
Although adverse reactions have been reported in these
time-proof variants (21e27), adverse events appear to be
much less common after recent advances in purification
technology.
Time and cost-effectiveness of the procedure
Native-type hyaluronate is a commercially available
product that is inexpensive compared with the cross-linked
type, which costs 60 times more. Injection of the gel takes
only a few minutes.
Advantage of brachytherapy in reirradiation
Because of the steep dose attenuation with distance,
interstitial brachytherapy is advantageous over IMRT. In
IMRT and most other types of external beam radiotherapy,
the size of surrounding high-dose area is generally propor-
tional to the size of the target; in addition, the available angle
range is often strictly limited to avoid previously irradiated
critical organs, such as the spinal cord and kidney as in the
present case.Conclusion
We consider that the HGI procedure is helpful for
improving the therapeutic ratio of HDRBT in curative dose
reirradiation of PALNM.References
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